Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)-Reference-Cited by-同舟云学术

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Published:2022-06-17 Issue:7 Volume:6 Page:e741
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Rüfer Axel,Angermann Hubert,Benz Rudolf,Bonadies Nicolas,Calderoni Antonello,Cantoni Nathan,Efthymiou Anna,Escher Robert,Favre Geneviève,Friess Dorothea,Gschwend Andreas,Himmelmann Andreas,Holbro Andreas,Keller Peter,Kouroupi Eirini,Lehmann Thomas,Pedarnig Nikolaus,Rigamonti Véronique,Samii Kaveh,Schmidt Adrian,Schäfer Hans-Peter,Sperb Roland,Stüssi Georg,Winkler Annette,Zenhäusern Reinhard,Goede Jeroen S.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference6 articles.

1. Myelodysplastic syndromes.;Cazzola;N Engl J Med,2020

2. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.;Malcovati;Blood,2013

3. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.;Fenaux;Ann Oncol,2021

4. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.;List;N Engl J Med.,2006

5. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.;Fenaux;Blood,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?;Blood Cancer Journal;2024-03-18

2. Clinical decision-making and treatment of myelodysplastic syndromes;Blood;2023-12-28